OSLO, Norway, Jan. 12, 2022 /PRNewswire/ -- Targovax ASA
(OSE: TRVX) a clinical stage immuno-oncology company developing
immune activators to target hard-to-treat solid tumors, today
announces that Innovation Norway has awarded Targovax an
NOK 8.2m grant to accelerate product
development activities related to the company's TG mutant RAS
vaccine program and planned clinical trials.
Awarded by: Innovation Norway
Granted amount: NOK 8.2m
Time frame: 2022-2024
Kristin Willoch Haugen,
Director of Innovation Norway Oslo Viken, commented: "Through
this project Targovax and their partners aim to solve an important
part of the great, international societal challenge that cancer
represents. Innovation Norway has
awarded a significant grant to reduce the development risk in the
project, which we believe has a high level of innovation and a
great potential for value creation in Norway. The Research Council of Norway has also contributed with funding to
this exciting project. "
Dr. Erik Digman Wiklund, CEO
of Targovax, added: "We are very pleased to be awarded yet
another prestigious grant towards our mutant RAS vaccines, this
time from Innovation Norway. Targovax's TG program is set up to
develop innovative novel immunotherapies that target critical
mutations in KRAS, a key driver of around 30% of all cancers. With
the support from Innovation Norway, we have now secured a total of
up to NOK 18m in grant funding, which
will allow us to move the TG program forward faster and more
broadly, and thus bring benefit to a patient group with poor
prognosis and few available treatment options."
For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@targovax.com
Renate Birkeli, Investor
Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com
Media enquires:
Andreas Tinglum - Corporate
Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/targovax/r/targovax-asa--targovax-awarded-nok-8-2m-grant-by-innovation-norway,c3484747